使用SAT-001治疗近视低龄儿童的数字疗法研究(DAYS):一项随机对照试验的研究方案
本研究为一项双臂、前瞻性、随机、开放标签临床试验,计划纳入110例5至<9岁、每眼球镜等效-0.75 D至-5.75 D的近视患儿,按1:1随机分为使用SAT-001联合单光眼镜的研究组或单用单光眼镜的对照组,主要终点为48周时球镜等效屈光误差(SER)较基线的变化,以评估SAT-001软件作为医疗器械抑制儿童近视进展的有效性和安全性。
要点
- SAT-001是用于近视控制的新型数字治疗软件,本研究旨在评估其疗效与安全性。
- 主要终点为48周时SER较基线的变化,次要终点包括24周时SER变化及每12周眼轴长度变化。
- 研究计划纳入110例5至<9岁近视患儿,随机1:1分组,疗程最长52周。
研究设计与样本
- 本研究为双臂、前瞻性、随机、开放标签临床试验,研究持续时间约25个月,参与者参与最长52周。
- 计划纳入110例5至<9岁近视患儿,每眼球镜等效为-0.75 D至-5.75 D。
- 符合条件者按1:1比例随机分配至使用SAT-001联合单光眼镜的研究组或单用单光眼镜的对照组。
主要发现
- 主要终点为48周时球镜等效屈光误差(SER)较基线的变化。
- 次要终点为24周时SER较基线的变化以及每12周眼轴长度较基线的变化,各变化将根据近视严重程度进行评估。
- 安全性分析将评估治疗中出现的不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需要进一步研究以验证SAT-001对中高度近视以及散光等并发情况的有效性。
- 原文指出需要进一步研究以提高用户参与度、丰富项目内容并与医院治疗相结合。
- 试验注册为回顾性注册(注册日期:2024年4月12日)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myopia is a prevailing refractive disorder and rapidly increases the risk of vision-threatening conditions. Earlier intervention is crucial to suppress myopia progression; however, the pharmacological and non-pharmacological therapies currently available have limitations. SAT-001 is a novel digital therapeutic software developed for myopia control and is designed to overcome the limitations of existing therapies. The present study aims to evaluate the efficacy and safety of the software as a medical device, SAT-001, for the inhibition of myopia progression and treatment in pediatric patients with myopia. METHODS: This clinical trial is a two-arm, prospective, randomized, open-label study with a duration of approximately 25 months, comprising a maximum of 52 weeks of participant participation. We will enroll 110 pediatric patients with myopia aged 5 to < 9 years, each with a spherical equivalent of - 0.75 D to - 5.75 D in each eye. Eligible participants will be randomly assigned in a 1:1 ratio to either the study group using SAT-001 with single-vision spectacles or the control group using single-vision spectacles alone. The change in the spherical equivalent refractive error (SER) at 48 weeks from baseline serves as the primary endpoint. The change in SER at 24 weeks and axial length at every 12 weeks from baseline will be the secondary endpoints. Each change will be assessed depending on the myopic severity. Treatment emergent adverse events will be evaluated for the safety analysis. DISCUSSION: This randomized controlled trial aims to confirm the efficacy and safety of SAT-001 in slowing pediatric myopia progression. The findings of this study could establish SAT-001 as an easily accessible, convenient, and non-invasive treatment option with minimal side effects, offering long-term myopia control from an early stage. Further research is needed to validate the effectiveness of SAT-001 for moderate to high myopia and concurrent conditions like astigmatism and to improve user engagement, diversify the program, and integrate with hospital-based treatments. TRIAL REGISTRATION: ClinicalTrials.gov: NCT06344572 ; date of registration: April 12, 2024 (retrospectively registered).
引用
- Paik HJ, Lee BJ, Lim DH, et al. Digital therapeutics approach for young children with myopia using SAT-001 (DAYS): study protocol for a randomized controlled trial. Trials. 2025. PMID: 40200346. doi:10.1186/s13063-025-08717-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。